Jack Fuchs

Mentor, Board member, investor in private companies

📍 San Mateo, California, United States🔄 Updated September 2026💼 10 investments📅 16 years investing🗓 Last invested Jan 2022
VC🌍 United States
10
Total investments
5
Early stage
1
Mid stage
1
Late stage
16y
Years active

Portfolio

8 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Jan 2022
Datch is a platform that leverages AI to capture highly detailed, structured human-centric data while surfacing asset insights for decision-making and resource management. Our goal is to cut deep into the availability shortfall by providing the data and intelligence needed to decrease asset MTTR, increase MTBF, support better planning and allow for faster decision making. In order to support the asset availability goals across resource management, reporting, planning, scheduling, and reliability, the product is designed around a single value proposition: ”perfect data”. By perfect data, we mean complete, highly accurate, context rich reports coming in from the frontline, and perfect recall and distillation of data to the right people at the right time. Data capture is achieved through a combination of worker enablement capabilities, such as speech-to-text, real-time translation, and conversational AI, and data enrichment, through features that add context and guidance to transform the data as it’s captured. Data accessibility and asset insights are tools that are underpinned by generative search trained on the company’s document management system, work management history, and other language-rich data sources related to assets.
Board Member
Jun 2018
Brazils leading investment fund manager in technology, Confrapar has an excellent track record, with more than 20 companies in the portfolio. The manager has the experience of more than 100 shareholders, a select group of investors distributed among different segments, in the technology, media and telecommunications industries. Among the quota holders are family offices, corporate ventures, funds of funds, banks and Brazilian and foreign development agencies.
Board Observer
Jan 2018
Ceres Nanosciences Inc. ("Ceres"​) is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology. The Nanotrap® technology, coupled with existing research and clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres currently sells the Nanotrap® technology for use in a broad range of research and diagnostic applications.
Board Member
2013
Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale Subscribe to our newsletter: http://eepurl.com/huCdiH
Investor
2012
Somos a maior empresa de tecnologia para eventos e experiências de entretenimento da América Latina.
early stageEvents Services
Board Member
2012
Aperia Technologies makes transportation more efficient, safer, and better for the environment. The company’s Halo Tire Management® platform improves fuel economy and road safety while reducing tire expenditures, downtime, and maintenance costs for commercial fleets. Aperia offers the most comprehensive, user-friendly line-up of tire management solutions available to commercial fleets worldwide including Halo® Tire Inflator, Halo Connect®, and Halo Connect i3®.
Investor
2011
Teleportd helps professional make sense of social photos and better leverage them. We're currently building Nitrogram: Advanced Analytics and Social Media Marketing Platform for Instagram. Measure, benchmark and boost your presence on Instagram. Boom!
Board Member
Jan 2010
Founded in 2009 and headquartered in the San Francisco Bay Area, Motiv Power Systems delivers medium-duty commercial all-electric trucks and buses, along with charging infrastructure and guidance for deploying commercial fleets. Specializing in step vans, shuttle buses, and box trucks, Motiv is an innovative provider of daily-use zero-emission vehicles for moving people and goods with 98% uptime and intense customer-driven focus. The company’s solutions not only offer fleets up to 85% operations and maintenance cost savings but also provide operators and riders a healthier and more comfortable experience without polluting the communities they serve. For more information about the company’s products, services, or career opportunities, please visit motivps.com.
Experience · 11 entries
All (11)
Investments (10)
Board (8)
2022
Board Member
Jan 2022
Datch is a platform that leverages AI to capture highly detailed, structured human-centric data while surfacing asset insights for decision-making and resource management. Our goal is to cut deep into the availability shortfall by providing the data and intelligence needed to decrease asset MTTR, increase MTBF, support better planning and allow for faster decision making. In order to support the asset availability goals across resource management, reporting, planning, scheduling, and reliability, the product is designed around a single value proposition: ”perfect data”. By perfect data, we mean complete, highly accurate, context rich reports coming in from the frontline, and perfect recall and distillation of data to the right people at the right time. Data capture is achieved through a combination of worker enablement capabilities, such as speech-to-text, real-time translation, and conversational AI, and data enrichment, through features that add context and guidance to transform the data as it’s captured. Data accessibility and asset insights are tools that are underpinned by generative search trained on the company’s document management system, work management history, and other language-rich data sources related to assets.
2018
Board Member
Jun 2018
Brazils leading investment fund manager in technology, Confrapar has an excellent track record, with more than 20 companies in the portfolio. The manager has the experience of more than 100 shareholders, a select group of investors distributed among different segments, in the technology, media and telecommunications industries. Among the quota holders are family offices, corporate ventures, funds of funds, banks and Brazilian and foreign development agencies.
Board Observer
Jan 2018
Ceres Nanosciences Inc. ("Ceres"​) is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology. The Nanotrap® technology, coupled with existing research and clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres currently sells the Nanotrap® technology for use in a broad range of research and diagnostic applications.
2017
Blackhorn Ventures
Operating Partner
Jul 2017
2016
Focal Systems
Board Observer
May 2016
Show all 11 entries ↓
Investment activity
2010–2022 · 10 investments
2010120111201222013120151201612018220221
Recent (last 2 years)Earlier